Loading…
← CockpitCompetitor Analysis › 196170.KS ALTEOGEN Inc.Open in the cockpit ↗

ALTEOGEN Inc.196170.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Biotechnology

Korean biotech that licenses a hyaluronidase enzyme technology converting IV biologic drugs into subcutaneous injections.

≈ Korea's Halozyme — the rival subcutaneous drug-delivery enzyme maker.Momentum laggard 9
Mkt cap
$8.80B
US dollars, full cap
Free float
80%
of shares outstanding
$/day
$67.1M
20-day average traded
Fwd P/E
42.0×
forward earnings
ROIC−WACC
+45.3 pp
WACC 7.0%
Hurdle
-14 pp
Req g minus delivered
Next earnings
124 days
22 Mar 2027
Close · KRW₩170,900
1D-1.2%
1W-6.9%
1M-26.0%
3M-45.6%
6M-55.6%
YTD-62.0%
1Y-68.8%
ATR %8.2%
52w lowhigh70.0% off high

What ALTEOGEN does

Korean biotech that licenses a hyaluronidase enzyme technology converting IV biologic drugs into subcutaneous injections.

Earns by licensing its enzyme to drug companies for upfront payments when a deal is signed, milestone payments as development proceeds, and royalties once the injectable form is sold, so income is lumpy and depends on partners' launches. Merck's subcutaneous Keytruda, approved in 2025, is the most prominent product using it.

In one line: Korea's Halozyme — the rival subcutaneous drug-delivery enzyme maker..

Products and services

  • ALT-B4 hyaluronidase licensing (Hybrozyme platform)
  • Long-acting biologics pipeline (fusion proteins)
  • Biosimilar development

Customers

  • Merck (MSD)
  • Novartis
  • AstraZeneca
  • other global pharma licensees

Where it sits in the supply chain

  • Biopharmaceuticals
  • Drug-delivery enabling technology
  • Hybrozyme recombinant hyaluronidase…

What could go right

  • Royalty/milestone income as licensed subcutaneous drugs launch
  • New licensing deals (Novartis, AstraZeneca)

What could go wrong

  • Halozyme patent litigation against Alteogen's licensees
  • Dependent on partners' drug approval and commercial success

Moat: narrow (IP/patents, switching costs). Patented enzyme technology is now embedded in approved drugs like Keytruda Qlex, though it faces Halozyme patent litigation.

Headquarters: Daejeon, South Korea · Founded: 2008 · Employees: 161

Named competitors

ALTEOGEN at a glance

Size ALTEOGEN (196170.KS) is a South Korea Health Care company (Biotechnology) with a market value of $8.80B, the 51st largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩170,900 on 18 Nov 2026.

Performance Over six months the shares fell 55.6%, against +24.1% for the median peer and -37.2% for the South Korea market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue grew 60.6% over the last twelve months (peer median +25.2%); the operating margin is 53.0% (peer median 8.5%).

Valuation It trades at 42.0× forward earnings against a peer median of 35.0× (4th most expensive of 11).

Price implies For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +38%, so the hurdle is -14 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 45.3 points above its cost of capital (7.0% WACC).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

5010021 May 202621 Aug 202618 Nov 2026Peer median 124196170.KS 46
Six months, rebased to 100: ALTEOGEN against the median of its 20 peers (local-currency closes).

ALTEOGEN financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩325B₩216B₩103B₩96.5B₩28.8B
Revenue growth—+110%+7%+235%—
Gross profit₩299B₩176B₩81.4B₩82.2B₩9.41B
EBITDA₩183B₩112B₩28.3B-₩6.40B-₩26.7B
Net income₩212B₩142B₩62.3B-₩3.37B-₩8.15B
Free cash flow₩116B₩101B₩50.3B-₩8.98B-₩24.2B
Capital expenditure₩38.0B₩33.4B₩24.5B₩43.5B₩42.5B
Total debt₩108B₩101B₩102B₩83.8B₩85.5B

Quarterly statements and history in the cockpit →

ALTEOGEN competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%1548SMMTPCVXKRYSTWST002422TXGKYMRCGONHALOAXSMIMVTTECHBMRN1093KODARWRSRRKELANCAI196170.KS6-month return →1-month return →
Up and to the right = strong over both horizons. ALTEOGEN is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×100×200×300×1548KRYS002422HALOAXSMTECHBMRN1093ELANCAI196170.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. ALTEOGEN is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%1548KRYS002422TXGHALOTECHBMRN1093ELANCAI196170.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. ALTEOGEN is the large dot.

ALTEOGEN competitors and peer comparison

Head to head with its named competitors (196170.KS vs HALO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
ALTEOGEN 196170.KS$8.80B-56%+61%53%42.0×24.6%
Halozyme Therapeutics HALO$10.9B+39%+45%57%9.5×-0.3%

How ALTEOGEN compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

ALTEOGEN against its 20 peers (data as of 18 Nov 2026)
Measure196170.KSPeer medianRank in peer set
1-month return-26.0%-5.4%4th lowest of 21
6-month return-55.6%+24.1%lowest of 21
Distance from 52-week high-70.0%-26.2%lowest of 21
Revenue growth (TTM)+60.6%+25.2%4th highest of 16
Operating margin53.0%8.5%2nd highest of 17
Forward P/E42.0×35.0×4th most expensive of 11
Growth the price implies (Req g, 7 yrs)24.6%15.7%5th most demanding of 11
Growth delivered (Del g)+38.5%+14.3%3rd highest of 11
Hurdle (Req g minus delivered)-13.9 pp+0.0 pp3rd least demanding of 11
ROIC minus cost of capital+45.3 pp-1.5 pphighest of 14
EV / EBITDA62.2×23.7×most expensive of 9
Net debt / EBITDA-1.8×-1.0×5th least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
ALTEOGEN 196170.KSSouth Korea$8.80B-56%+61%53%42.0×24.6%+38.5%
Genscript Biotech 1548.HKHong Kong$8.69B+133%+53%12%294.1×36.9%+19.8%
Summit Therapeutics SMMTUnited States$8.40B-41%n/an/an/an/an/a
Vaxcyte PCVXUnited States$9.26B+24%n/an/an/an/an/a
Krystal Biotech KRYSUnited States$9.34B+4%+26%48%36.3×13.1%+26.0%
Twist Bioscience TWSTUnited States$7.93B+117%+22%-29%n/an/an/a
Sichuan Kelun Pharmaceutical 002422.SZChina$10.1B+35%0%9%35.6×6.2%+2.3%
10x Genomics TXGUnited States$7.51B+138%-4%-11%n/a47.2%+16.6%
Kymera Therapeutics KYMRUnited States$10.3B+50%+134%-396%n/an/an/a
CG Oncology CGONUnited States$7.15B+24%+184%-4,294%n/an/an/a
Halozyme Therapeutics HALOUnited States$10.9B+39%+45%57%9.5×-0.3%+39.2%
Axsome Therapeutics AXSMUnited States$7.05B-42%+54%-19%77.1×n/an/a
Immunovant IMVTUnited States$6.86B-7%n/an/an/an/an/a
Bio-Techne TECHUnited States$11.4B+56%+1%21%34.4×31.6%+5.5%
BioMarin Pharmaceutical BMRNUnited States$11.9B+22%+20%19%11.2×8.2%+12.0%
Cspc Pharma 1093.HKHong Kong$12.0B+10%+25%28%9.1×-10.7%+0.1%
Kodiak Sciences KODUnited States$6.40B+170%n/an/an/an/an/a
Arrowhead Pharmaceuticals ARWRUnited States$6.09B-44%-46%-157%n/an/an/a
Scholar Rock SRRKUnited States$5.86B-1%n/a-71,732%n/an/an/a
Elanco Animal Health ELANUnited States$13.3B+28%+12%8%21.5×32.9%+7.6%
Caris Life Sciences CAIUnited States$5.59B+24%+61%13%79.4×18.2%+61.5%

Questions

Who are ALTEOGEN's main competitors?
Named competitors: Halozyme Therapeutics (HALO). The cockpit's measured peer set (industry) also includes Genscript Biotech (1548.HK), Summit Therapeutics (SMMT), Vaxcyte (PCVX), Krystal Biotech (KRYS), Twist Bioscience (TWST), Sichuan Kelun Pharmaceutical (002422.SZ).
Is ALTEOGEN expensive compared with its peers?
On forward p/e it trades at 42.0× against a peer median of 35.0×, 4th most expensive of 11 in its peer set. For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +38%, so the hurdle is -14 pp: the price already allows for a slowdown.
How has ALTEOGEN stock performed?
Over six months to 18 Nov 2026 the shares returned -55.6% against +24.1% for the median peer; over one year -68.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.